Management of Severe Hyperglycemia in ESRD Patients

Introduction to Insulin Therapy

• The American Diabetes Association recommends initiating insulin therapy for persistent hyperglycemia ≥180 mg/dL in hospitalized patients, and a glucose of 664 mg/dL clearly exceeds this threshold, requiring immediate intervention 1
• The target glucose range during intravenous insulin therapy is 140-180 mg/dL for most critically ill patients, which applies to ESRD patients as well 1
• Insulin therapy should be initiated with caution, as ESRD patients have impaired insulin clearance by the kidney, defective insulin degradation due to uremia, and failed renal gluconeogenesis—all of which dramatically increase hypoglycemia risk during insulin therapy 2

Critical Monitoring Requirements

• Point-of-care glucose monitoring should occur every 30 minutes to 2 hours during intravenous insulin infusion, which is the required standard for safe insulin drip use 1
• ESRD patients require more intensive monitoring than standard protocols due to multiple factors that increase hypoglycemia risk 2

Key Modifications for ESRD Patients

• Expect increased insulin sensitivity and reduced insulin requirements compared to patients with normal renal function, as the kidney normally metabolizes up to 80% of exogenous insulin 3
• Be prepared to reduce insulin infusion rates more aggressively than standard protocols once glucose begins declining, as ESRD patients commonly experience wide glycemic excursions with rapid swings between hyperglycemia and hypoglycemia 2
• If the patient is on hemodialysis, recognize that dialysis sessions can precipitate hypoglycemia through increased erythrocyte glucose uptake during treatment, requiring potential insulin dose adjustments or temporary discontinuation 2

Avoiding Common Pitfalls

• Do not rely solely on HbA1c for long-term glycemic assessment in ESRD, as it is falsely lowered by anemia, erythropoietin use, reduced erythrocyte lifespan from uremia, and frequent blood transfusions 4, 3
• Ensure the glucose meter is not glucose dehydrogenase-based if the patient uses icodextrin-containing peritoneal dialysis solutions, as these cause falsely elevated readings (pseudo-hyperglycemia) 2

Transition Planning and Concurrent Medication Review

• Target an HbA1c range of 7-8% for long-term management in ESRD patients, as this appears most favorable based on observational data showing associations with mortality and hypoglycemia risk 2
• Consider continuous glucose monitoring (CGM) after discharge, as emerging data suggest it provides more precise monitoring and helps detect asymptomatic hypoglycemia in ESRD patients 5, 2
• SGLT2 inhibitors are contraindicated in ESRD and should be discontinued 5

End-Stage Kidney Disease (ESKD) Guidelines

Etiology of ESKD

• Diabetes is the leading cause of ESKD requiring renal replacement therapy worldwide, accounting for approximately half of all cases of ESKD worldwide 6, 7
• The prevalence of diabetes in ESKD patients ranges from 66% to 86% depending on age and race/ethnicity 7
• Diabetes is more prevalent in ESKD than in earlier CKD stages because it may co-occur with other causes of CKD or develop after ESKD, particularly in kidney transplant recipients 7

Morbidity and Mortality in ESKD

• Treatment of ESKD by hemodialysis is associated with poor long-term survival, with an adjusted survival after 3 and 5 years of hemodialysis initiation of only 55% and 40%, respectively 7
• Patients with diabetes have the worst adjusted-survival rates among the ESKD population 7
• Hypertension is extremely common in advanced CKD, with prevalence approaching 80% in those with stage 4 CKD 8

Complications of Dialysis

• Peritonitis is a major complication of peritoneal dialysis 9
• Peritoneal dialysis solutions containing glucose can interfere with glucose monitoring devices, particularly those using glucose dehydrogenase-based–pyrroloquinoline-quinone/glucose oxidase–based glucose meters 10
• Hypoglycemia is a common acute complication of hemodialysis 11, 12

Acute Complications of Hemodialysis

• Patients with diabetes on hemodialysis commonly experience hypoglycemic episodes that require adjustment or discontinuation of insulin and oral antihyperglycemic agents 11
• Several mechanisms contribute to hypoglycemia during hemodialysis, including:

Management Considerations in ESKD

• Kidney transplantation typically yields the best patient outcomes compared to dialysis, with data showing 70% reduced mortality among patients with ESKD who underwent transplantation compared to non-transplanted counterparts 9

Management of Fatigue and Severe Hyperglycemia in Hemodialysis Patients

Glycemic Management

• The Kidney International guideline recommends reducing insulin doses more aggressively than standard protocols once glucose begins declining, and being prepared to adjust or temporarily discontinue insulin around hemodialysis sessions due to increased erythrocyte glucose uptake during dialysis, with evidence from Endocrine Reviews 13

Addressing Fatigue

• The Kidney International guideline suggests addressing fatigue through a combination of physical exercise, optimization of dialysis adequacy, and screening for common contributing factors including anemia, malnutrition, depression, and inadequate dialysis, with moderate-quality evidence 14
• Implementing aerobic exercise programs tailored to the patient's ability decreases both fatigue and depressive symptom burden in hemodialysis patients, with moderate-quality evidence from Kidney International 14
• Cognitive behavioral therapy is effective in reducing depression in dialysis patients, with existing evidence from Kidney International 14
• Manual acupressure has shown short-term benefits as an adjuvant intervention for fatigue in small-scale studies from Kidney International 14
• Addressing socioeconomic factors such as food and housing insecurity contributes to symptom burden, with evidence from Kidney International 14
• Ruling out depression is crucial, as it is highly prevalent in dialysis patients and manifests as fatigue, with evidence from Kidney International 14

Blood Pressure Management

• Maintaining vigilance for both intradialytic hypotension and hypertension is crucial, as any symptomatic BP decrease or nadir intradialytic SBP <90 mm Hg should prompt reassessment of ultrafiltration rate, dialysis treatment time, interdialytic weight gain, dry-weight estimation, and antihypertensive medications, with evidence from Kidney International 15
• Avoiding overly low blood pressures is recommended, as numerous observational studies and the Blood-Pressure-in-Dialysis trial have suggested harm from lower BPs in dialysis patients, with evidence from Kidney International 15
• Focusing on volume management through adequate dialysis and sodium restriction rather than fluid restriction alone is the primary determinant of blood pressure in dialysis patients, with evidence from Kidney International 15

Medication Management

• Avoiding polypharmacy is crucial, as elderly ESRD patients account for over 177,000 emergency visits annually for adverse drug events, with insulin being implicated in 13.9% of hospitalizations, with evidence from Diabetes Care 16